{
    "ticker": "OGEN",
    "name": "Oragenics, Inc.",
    "description": "Oragenics, Inc. is a biotechnology company focused on the development of innovative treatments for infectious diseases and oral health. Established in 1996, the company is dedicated to advancing the science of probiotics and combating antibiotic-resistant bacteria through its proprietary technologies. Oragenics is known for its flagship product, 'AG013', a novel therapeutic candidate designed to treat oral mucositis, a painful inflammation of the mucous membranes in the mouth that can occur during cancer treatments. The company is also engaged in the development of its 'S.G. 202' program, which aims to address various infectious diseases with a focus on improving patient outcomes. With a strong commitment to research and development, Oragenics collaborates with academic institutions and industry partners to enhance its product pipeline and foster innovations in microbial therapeutics. The company's mission is to provide solutions that improve the quality of life for patients suffering from debilitating conditions. Oragenics is at the forefront of microbiome research, leveraging its expertise to explore new avenues in disease prevention and treatment.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Tampa, Florida, USA",
    "founded": "1996",
    "website": "https://www.oragenics.com",
    "ceo": "Alfredo J. R. B. De La Torre",
    "social_media": {
        "twitter": "https://twitter.com/Oragenics",
        "linkedin": "https://www.linkedin.com/company/oragenics-inc/"
    },
    "investor_relations": "https://ir.oragenics.com",
    "key_executives": [
        {
            "name": "Alfredo J. R. B. De La Torre",
            "position": "CEO"
        },
        {
            "name": "Gary E. D. K. S. G. W. E. G. H. C. H. W. D. G. M. C.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "AG013",
                "S.G. 202"
            ]
        }
    ],
    "seo": {
        "meta_title": "Oragenics, Inc. | Biotechnology Solutions for Infectious Diseases",
        "meta_description": "Explore Oragenics, Inc., a biotechnology company focused on developing innovative therapeutics for infectious diseases and oral health.",
        "keywords": [
            "Oragenics",
            "Biotechnology",
            "Infectious Diseases",
            "Probiotics",
            "Oral Health",
            "AG013"
        ]
    },
    "faq": [
        {
            "question": "What does Oragenics specialize in?",
            "answer": "Oragenics specializes in developing innovative treatments for infectious diseases and oral health."
        },
        {
            "question": "Who is the CEO of Oragenics?",
            "answer": "Alfredo J. R. B. De La Torre is the CEO of Oragenics, Inc."
        },
        {
            "question": "Where is Oragenics headquartered?",
            "answer": "Oragenics is headquartered in Tampa, Florida, USA."
        },
        {
            "question": "What are Oragenics' main products?",
            "answer": "Oragenics' main products include AG013 and the S.G. 202 program."
        },
        {
            "question": "When was Oragenics founded?",
            "answer": "Oragenics was founded in 1996."
        }
    ],
    "competitors": [
        "AMRN",
        "BCRX",
        "VSTM"
    ],
    "related_stocks": [
        "GILD",
        "BIIB",
        "ABBV",
        "MRNA"
    ]
}